| Literature DB >> 30609645 |
Wenjuan Qian1,2,3, Jinjun Shan4,5, Cunsi Shen6,7, Rui Yang8,9, Tong Xie10,11, Liuqing Di12,13,14.
Abstract
Pyrexia is considered as a part of host's defense response to the invasion of microorganisms or inanimate matter recognized as pathogenic or alien, which frequently occurs in children. Jinxin oral liquid (JXOL) is a traditional Chinese medicine formula that has been widely used to treat febrile children in China. Experimental fever was induced by injecting yeast into young male Sprague-Dawley rats (80 ± 20 g) and the rectal temperature subsequently changed. Four hours later, the excessive production of interleukin (IL)-1β and prostaglandin (PG) E2 induced by yeast was regulated to normal by JXOL administration. A rat brain metabolomics investigation of pyrexia of yeast and antipyretic effect of JXOL was performed using gas chromatography-mass spectrometry (GC-MS). Clear separation was achieved between the model and normal group. Twenty-two significantly altered metabolites were found in pyretic rats as potential biomarkers of fever. Twelve metabolites, significantly adjusted by JXOL to help relieve pyrexia, were selected out as biomarkers of antipyretic mechanism of JXOL, which were involved in glycolysis, purine metabolism, tryptophan mechanism, etc. In conclusion, the brain metabolomics revealed potential biomarkers in the JXOL antipyretic process and the associated pathways, which may aid in advanced understanding of fever and therapeutic mechanism of JXOL.Entities:
Keywords: Jinxin oral liquid; biomarkers; gas chromatography-mass spectrometry; metabolomics; pyrexia
Year: 2019 PMID: 30609645 PMCID: PMC6359216 DOI: 10.3390/metabo9010006
Source DB: PubMed Journal: Metabolites ISSN: 2218-1989
Figure 1Antipyretic and anti-inflammation effects of IB and JXOL. A: The rectal temperatures were measured at 0, 30, 60, 90, 120, 180, and 240 min after drug administration. B: Effects of JXOL on the production of IL-1β and PGE2. (# p < 0.05, ## p < 0.01, vs. NG; * p < 0.05, ** p < 0.01, vs. MG).
Figure 2Typical GC-MS total ion chromatograms (TIC) of brain samples from NG, MG, IBG, and JXG.
Figure 3PCA scores scatter plot of brain metabolites.
Figure 4Scatter plots of significantly changed metabolites’ normalized peak intensity in rat brain samples. The x-axis shows the specific metabolite’s normalized peak intensity, and each scatter represents a rat brain sample. represents brain samples of NG, represents brain samples of MG, represents brain samples of IBG, and represents brain samples of JXG. The scatter plots show the mean and SD of the metabolites. # p < 0.05, ## p < 0.01, vs. NG; * p < 0.05, ** p < 0.01, vs. MG.
Potential biomarkers of pyrexia.
| NO. | Metabolites | HMDB | KEGG | FC | |||
|---|---|---|---|---|---|---|---|
| MG vs. NG | IBG vs. MG | JXG vs. MG | |||||
| 1 | 3-phosphoglycerate | HMDB0000807 | C00597 | 0.455 | <0.0001 ## | 0.0040 ** | <0.0001 ** |
| 2 | 5-6-dihydrouracil | HMDB0000076 | C00429 | 1.506 | 0.0010 ## | <0.0001 ** | 0.8870 |
| 3 | 5′-deoxy-5′-methylthioadenosine | HMDB0001173 | C00170 | 1.705 | 0.0020 ## | <0.0001 ** | <0.0001 ** |
| 4 | adenine | HMDB0000034 | C00147 | 1.814 | 0.0080 ## | 0.0400 * | <0.0001 ** |
| 5 | adenosine | HMDB0000050 | C00212 | 0.658 | <0.0001 ## | 1.0000 | 0.1070 |
| 6 | adenosine-5-monophosphate | HMDB0000045 | C00020 | 1.734 | <0.0001 ## | 0.1380 | 0.6430 |
| 7 | alpha-aminoadipic acid | HMDB0000510 | C00956 | 0.623 | <0.0001 ## | 0.8180 | 0.8340 |
| 8 | arabitol | HMDB0000568 | C01904 | 1.939 | 0.0470 # | 0.0470 * | 0.4550 |
| 9 | aspartate | HMDB0000191 | C00049 | 0.589 | <0.0001 ## | 0.0400 * | 0.1390 |
| 10 | beta-hydroxybutyric acid | HMDB0000357 | C01089 | 0.631 | 0.0080 ## | 0.5000 | 0.0010 ** |
| 11 | creatine | HMDB0000064 | C00300 | 1.925 | <0.0001 ## | <0.0001 ** | 0.8870 |
| 12 | fructose-1-6-bisphosphate | HMDB0001058 | C00354 | 2.419 | <0.0001 ## | 0.0020 ** | 0.5190 |
| 13 | glyceric acid | HMDB0000139 | C00258 | 0.582 | <0.0001 ## | <0.0001 ** | <0.0001 ** |
| 14 | inosine | HMDB0000195 | C00294 | 2.273 | <0.0001 ## | <0.0001 ** | <0.0001 ** |
| 15 | HMDB0000212 | C01074 | 0.566 | <0.0001 ## | <0.0001 ** | <0.0001 ** | |
| 16 | HMDB0000812 | C01042 | 1.541 | <0.0001 ## | <0.0001 ** | <0.0001 ** | |
| 17 | pantothenic acid | HMDB0000210 | C00864 | 0.673 | <0.0001 ## | 0.0020 ** | <0.0001 ** |
| 18 | phosphogluconic acid | HMDB0001316 | C00345 | 1.624 | <0.0001 ## | 0.0010 ** | 0.4300 |
| 19 | pyruvic acid | HMDB0000243 | C00022 | 0.576 | <0.0001 ## | <0.0001 ** | <0.0001 ** |
| 20 | quinolinic acid | HMDB0000232 | C03722 | 2.116 | <0.0001 ## | 0.0010 ** | <0.0001 ** |
| 21 | tagatose | HMDB0003418 | C00795 | 0.391 | <0.0001 ## | 0.0030 ** | <0.0001 ** |
| 22 | uracil | HMDB0000300 | C00106 | 0.588 | <0.0001 ## | 0.0020 ** | <0.0001 ** |
# p < 0.05, ## p < 0.01, vs. NG; * p < 0.05, ** p < 0.01, vs. MG.
Figure 5The pathways closely associated with the antipyretic and anti-inflammation effects. Bold metabolites were potential biomarkers of yeast-induced fever; green bold metabolites were antipyretic biomarkers of JXOL.